Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pezzoli, G.
Right arrow Articles by Moscarelli, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pezzoli, G.
Right arrow Articles by Moscarelli, E.
NEUROLOGY 1995;45:S22-S27
© 1995 American Academy of Neurology

A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease

Gianni Pezzoli, MD, Emilia Martignoni, MD, Claudio Pacchetti, MD, Vita Angeleri, MD, Paolo Lamberti, MD, Alberto Muratorio, MD, Ubaldo Bonuccelli, MD, Michele De Mari, MD, Nicoletta Foschi, MD, Elisabetta Cossutta, MD, Francesco Nicoletti, MD, Giovanni Giammona, MD, Margherita Canesi, MD, Guglielmo Scarlato, MD, Tommaso Caraceni, MD and Elena Moscarelli, MD

From:1 Institute of Clinical Neurology, University of Milan,2 Department of Neurology, Neurological Institute, University of Pavia,3 Institute of Neurology, University of Ancona,4 Institute of Neurology, University of Bari,5 Institute of Clinical Neurology, University of Pisa,6 Department of Neurology, Neurological Institute C. Besta, Milan,7 Institute of Neuroscience, University of Catania, (8) Eli Lilly Italia, Sesto Fiorentino, Italy.
Address correspondence and reprint requests to Dr. Gianni Pezzoli, Ospedale Maggiore Pad Ponti, Institute of Clinical Neurology, via F. Sforza 35, I 20122 Milan, Italy.

A single-blind, crossover study was carried out to compare the efficacy and safety of pergolide against that of bromocriptine in 57 patients with Parkinson's disease who showed a declining response to levodopa therapy. Patients were randomly assigned to receive either bromocriptine followed by pergolide, or pergolide followed by bromocriptine. Both drugs were administered for 12 weeks. Patients were assessed by a clinician blinded to treatment assignment using the New York University Parkinson's Disease Scale. The average daily dose of pergolide was 2.3 plus minus 0.8 mg and of bromocriptine 24.2 plus minus 8.4 mg. Addition of pergolide or bromocriptine resulted in a significant improvement in total scores when compared with the previous treatment of levodopa alone (pergolide, p equals 0.0001; bromocriptine, p equals 0.0005). Pergolide was more effective than bromocriptine in daily living scores (p equals 0.02) and motor scores (p equals 0.038). No differences in the incidence of dyskinesias, dystonias, or psychosis were observed between groups. Fewer adverse events were recorded in the pergolide group, and most patients and physicians preferred pergolide to bromocriptine. Pergolide as adjunctive therapy to levodopa was more effective than bromocriptine in this short-term trial.

NEUROLOGY 1995;45(suppl 3): S22-S27.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.